Abstract
Abstract It is estimated that the etiology of 20-30% of epithelial cancers is directly associated with inflammation, though the molecular events linking inflammation and the necessary carcinogenic mutations remain to be clarified. In the context of gastrointestinal disease, the bacterial pathogens Helicobacter pylori and enterotoxigenic Bacteroides fragilis (ETBF) are significant sources of chronic inflammation and have been implicated as risk factors for the development of gastric and colorectal cancer, respectively. We have previously demonstrated that H. pylori and the cytokine tumor necrosis factor-α (TNF-α) rapidly induce spermine oxidase (SMO), resulting in increased cellular reactive oxygen species (ROS) and DNA damage, in gastric and lung epithelial cells. In addition, tissue microarray studies revealed that increased SMO expression was associated with prostatic intraepithelial neoplasia and prostate cancer lesions and that benign prostate epithelial tissue from men with these diseases exhibits higher SMO expression than normal controls. We now demonstrate that purified B. fragilis toxin (BFT) upregulates SMO in HT29/c1 and T84 colonic epithelial cells, resulting in SMO-dependent induction of γ-H2A.x, a marker of DNA damage. Further, ETBF-induced colitis in wild-type or APC+/− Min C57Bl/6 mice is associated with increased SMO expression. Inhibition of SMO activity by MDL 72,527 in vivo (20 mg/kg i.p. 3 days per week) significantly reduces ETBF-induced chronic inflammation, proliferation, and induction of Th17-associated cytokines. Most importantly, in Min mice, treatment with the SMO inhibitor reduces ETBF-induced colon tumorigenesis by 69% (p<.001). Our studies suggest that SMO is a novel target for chemopreventive or chemotherapeutic drug development. Citation Information: Cancer Prev Res 2010;3(12 Suppl):A56.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call